GLP-1 & metabolic / Compound guide

Liraglutide guide

Liraglutide is an FDA-approved GLP-1 receptor agonist.[1] The cited label describes a 3 mL prefilled pen containing 6 mg/mL. The library uses subcutaneous prescribing-information references rather than a powder-vial preparation model.

Editorial still life for glp-1 & metabolic research guides

ILLUSTRATION / COMPOUND LIBRARY SERIES

At a glance

Regulatory status
Liraglutide is an FDA-approved prescription medicine (first US approval 2010, per the cited label).[1]
Half-life
Approximately 13 hours (elimination half-life after a single subcutaneous dose), per the label.[1]
Route
Subcutaneous, per the label.[1]
Category
GLP-1 & metabolic
Vial size
18 mg

Liraglutide's 18 mg package already includes 3 mL of liquid in a prefilled pen. Its 13-hour reference describes elimination, not the volume or device setting. This card concerns a labeled pen presentation, even though adjacent library pages use powder-vial arithmetic.[1]

What the research says

The cited label describes subcutaneous liraglutide exposure in adults with obesity and pharmacokinetic studies in healthy participants. Investigators measured plasma concentrations and compared exposure across injection sites. The document reports approximately 55% absolute bioavailability and similar exposure from the abdomen, thigh, and upper arm.[1]

The cited label gives a peak concentration at about 11 hours and an elimination half-life of approximately 13 hours. Liraglutide exposure increased proportionally over the studied range. These measurements describe the time course of a peptide already supplied as a solution in a prefilled pen.[1]

A radiolabeled study in healthy participants examined metabolism and excretion. Intact liraglutide was the main plasma component during the initial day, while only small fractions of radioactivity appeared in urine and feces as related metabolites. The labeled product therefore supplies both formulation facts and human disposition context.[1]

Cited amounts

The label describes a 3 mL prefilled pen containing 18 mg (6 mg/mL). This is the total in that presentation, not an amount selected for administration. No personal dosing range is inferred from it.[1]

Open the calculator for amount conversions

Half-life and timing

Approximately 13 hours (elimination half-life after a single subcutaneous dose), per the label.[1]

Thirteen hours produces a different plotting scale from the week-long metabolic entries. The model reaches one quarter of its starting amount at 26 hours and one eighth at 39 hours. Its five-half-life point is 65 hours with 3.125% remaining. These calculated fractions neither include the source's eight- to 12-hour peak window nor account for additional recorded administrations. The resulting bar is a simplified illustration, not a personal clearance estimate and not an operating schedule for the pen.

Liraglutide: modeled fraction over five half-livesStarting at 100 percent, the model halves each 13 hours. After 65 hours, 3.125 percent remains. This is arithmetic, not a measured concentration. ELAPSED HOURS / MODELED STARTING AMOUNT 0 h100%13 h50%26 h25%39 h12.5%52 h6.25%65 h3.125% Continue to the calculator

Reconstitution

The labeled package supplies both parts of the concentration equation: 18 mg divided by 3 mL equals 6 mg/mL. For a dimensional check only, 0.1 mL at that concentration represents 0.6 mg. This does not instruct a reader to withdraw liquid from a pen or select a device setting. There is no added-water term in the example. The three milliliters are already supplied, and treating them as a proposed dilution would change the meaning of the label.

6 mg/mL × 0.1 mL = 0.6 mg
Open Liraglutide conversion math

Tracking it in PinPoint

From a reference to a record

Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Track vials and prefilled pens side by side.[2]

The Home curve models your levels between doses from an estimate built on the half-life value stored for each compound, published where a published value exists and an estimate where none does. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.

Get PinPoint on the App Store

Frequently asked questions

Does a liraglutide calculator require reconstitution water?
The referenced liraglutide presentation is a prefilled pen containing 18 mg in 3 mL. It is not the powder-vial example used for some research peptides. This page shows the labeled concentration arithmetic and does not provide pen-disassembly or water-addition instructions.[1]
Does a liraglutide mixing calculator apply to the referenced pen?
The source presentation is already prepared and contains 18 mg in 3 mL. This guide checks that concentration by division. It does not describe opening, diluting, or repurposing the pen, and it does not infer settings from a general reconstitution tool.[1]
Why keep liraglutide's peak window separate from its half-life?
The eight- to 12-hour peak window and the approximately 13-hour elimination reference describe different aspects of the source data. The simple halving bar uses only the latter. Combining them into one number would hide that distinction.[1]

Sources

Sources checked against the cited documents on 19 November 2026.

  1. Liraglutide injection 3 mg pen, prescribing information (DailyMed, SPL effective 25 February 2026)Read 19 November 2026: Highlights (initial US approval 2010), 3 Dosage forms, 11 Description, 12.3 Pharmacokinetics, Instructions for Use.Retrieved 2026-11-19 · label
  2. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description